<DOC>
	<DOCNO>NCT00274066</DOCNO>
	<brief_summary>To evaluate acute effect single dose ipratropium ( Atrovent ) fenoterol ( Berotec ) comparison placebo give COPD patient pharmacodynamic steady state tiotropium ( Spiriva )</brief_summary>
	<brief_title>Acute Bronchodilator Response Single Dose Atrovent Berotec Top Pharmacodynamic Steady State Spiriva</brief_title>
	<detailed_description>In case mono-bronchodilator therapy control symptom COPD adequately regular maintenance therapy desire , therapeutic intervention combination bronchodilator recommend . The risk side-effects increase increase dose drug , therefore , important rationale combination therapy favourable ratio efficacy safety . Knowing anticholinergic beta-adrenergic agent achieve bronchodilating effect different mechanism , particular combination agent proven beneficial management COPD . Based establish clinical benefit , tiotropium attractive promising agent first-line long-term maintenance therapy COPD . This also imply therapeutic intervention bronchodilator prescribe daily practice . At present study combination therapy short-acting agent available . Therefore , use double-blind , randomise , crossover design , bronchodilator effect single dos ipratropium fenoterol compare placebo add top steady state tiotropium . Patients pre-treated tiotropium achieve pharmacodynamic steady state . Serial lung function test ( FEV1 , FVC , Raw , sGaw ) conduct follow add-on short-acting bronchodilator placebo . Study Hypothesis : H0 : difference treatment mean peak FEV1 H1 : difference treatment mean peak FEV1 Comparison ( ) : Add-on placebo compare add-on ipratropium add-on fenoterol . The comparison ipratropium placebo primary . The 2 pair-wise comparison secondary .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Fenoterol</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<mesh_term>Bronchodilator Agents</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Inclusion : diagnosis COPD FEV1 &lt; 60 % predict FEV1 &lt; 70 % FVC smoking history 10 packyears Exclusion : significant disease COPD history asthma , allergic rhinitis blood eosinophil count &gt; 600mm3 cardiac arrhythmia require drug therapy symptomatic prostatic hypertrophy , bladder neck obstruction narrowangle glaucoma recent history MI ( within past year ) history cancer within past 5 year lifethreatening pulmonary obstruction cystic fibrosis bronchiectasis ; tuberculosis pulmonary resection</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>